文献速递分子诊断质量管理与危急值

超越拷贝数:循环游离线粒体DNA片段组学与结构状态在液体活检中的应用

Beyond copy number: circulating cell-free mitochondrial DNA Fragmentomics and structural states in liquid biopsy.
PubMed 文献 · Clin Chim Acta · 2026-09-14

循环游离线粒体DNA(cf-mtDNA)常被当作基于浓度的生物标志物,但其信号是多种生物學上不同的分子状态的复合,受采血、血小板活化、离心、储存、提取、扩增和测序等因素影响。本文综述将cf-mtDNA视为多维分析物,整合线粒体释放生物学与胞外载体状态,评估分析前和分析偏差,并探讨其在肿瘤、危重症、心肾疾病等领域的转化证据。核心提示是cf-mtDNA诊断的下一阶段更依赖于测量正确的分子组分而非更多DNA,需可追溯的分析前处理、正交表征和临床锁定的计算模型。

要点

  • cf-mtDNA信号是多种分子状态的复合,受分析前因素显著影响。
  • 片段大小、5‘端组成、基序多样性和区域断裂模式可支持癌症检测和组织溯源。
  • 需区分真实生物学变异与程序诱导的cf-mtDNA在可溶性、囊泡性、血小板相关和游离线粒体组分间的再分布。

核心结论

  • cf-mtDNA诊断的下一阶段更依赖于测量正确的分子组分而非更多DNA,需可追溯的分析前处理、正交表征和临床锁定的计算模型。

研究设计与样本

  • 本文为综述,整合线粒体释放生物学与cf-mtDNA胞外载体状态,评估分析前和分析偏差,并评价多队列研究及临床化学研究证据。

主要发现

  • 近期多队列研究表明片段大小、5’-端组成、基序多样性和区域断裂模式可支持癌症检测和组织溯源推断。
  • 临床化学研究显示常规分析前选择可显著改变从血浆中回收的线粒体组分。

临床怎么用

  • 建议将cf-mtDNA视为多维分析物,关注分析前和分析质量控制的优先事项及验证步骤。
  • 需区分真实生物学变异与程序诱导的cf-mtDNA在可溶性、囊泡性、血小板相关和游离线粒体组分间的再分布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Circulating cell-free mitochondrial DNA (cf-mtDNA) is commonly treated as a concentration-based biomarker, yet the measured signal is a composite of biologically distinct molecular states that are differentially affected by blood collection, platelet activation, centrifugation, storage, extraction, amplification, and sequencing. This analytical heterogeneity has become more consequential as cf-mtDNA research moves from copy-number assays toward fragmentomics, topology, heteroplasmy, oxidative lesions, and carrier-resolved measurements. Recent multi-cohort studies indicate that fragment size, 5'-end composition, motif diversity, and regional breakage patterns can support cancer detection and tissue-of-origin inference, while clinical chemistry studies demonstrate that routine preanalytical choices can markedly alter the mitochondrial fraction recovered from plasma. This review develops a laboratory-medicine framework in which cf-mtDNA is considered a multidimensional analyte rather than a single abundance variable. We integrate mitochondrial release biology with the extracellular carrier states of mtDNA; explain how TFAM, membrane pores, mitophagy, extracellular vesicles, platelets, and nucleases shape the observed fragmentome; evaluate preanalytical and analytical sources of bias; and assess translational evidence across oncology, critical illness, cardio-renal disease, metabolic inflammation, transplantation, and neuroinflammatory disorders. Particular emphasis is placed on distinguishing true biological variation from procedure-induced redistribution of cf-mtDNA between soluble, vesicular, platelet-associated, and cell-free mitochondrial compartments. We propose minimum analytical descriptors, quality-control priorities, and validation steps required before cf-mtDNA fragmentomic signatures can become transportable clinical tests. The central implication is that the next phase of cf-mtDNA diagnostics will depend less on measuring more DNA than on measuring the correct molecular fraction with traceable preanalytics, orthogonal characterization, and clinically locked computational models.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Naseem MT, Zaman W, Ullah A, et al. Beyond copy number: circulating cell-free mitochondrial DNA Fragmentomics and structural states in liquid biopsy. Clin Chim Acta. 2026. PMID: 42735774. doi:10.1016/j.cca.2026.121343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。